How much does Sunitinib cost?

Sunitinib was approved by the U.S. Food and Drug Administration (FDA) for the adjuvant treatment of adult patients at high risk for recurrence of renal cell carcinoma after nephrectomy. In the S-TRAC trial, 28% of patients permanently discontinued sunitinib and 61% required dose reduction or interruption. Therefore, although one year of sunitinib is highly toxic, it may be acceptable in patients with a high risk of relapse.

Sunitinib is approved for the adjuvant treatment of adult patients with renal cell carcinoma at a dose of 50 mg orally once daily for 4 weeks followed by 2 weeks off, for a total of nine 6-week cycles. Can be taken with or without food, sunitinib's toxicity profile is similar to that seen in patients with advanced renal cell carcinoma, and prescribers need to weigh these risks against the potential benefits for each patient. Common adverse reactions (≥25%) are fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/taste changes, dyspepsia, and thrombocytopenia.

The original sunitinib drug has been launched in China and has entered the scope of Class B medical insurance. SpecificationsThe price of 12.5mg*28 tablets is around RMB 3,500. The original sunitinib drug has also been launched overseas. The price of 12.5mg*7 tablets is around RMB 1,500 (the price may fluctuate due to the exchange rate). There are also generic drugs produced in other countries. The price of 12.5mg*28 tablets produced by an Indian pharmaceutical factory is around RMB 750 (the price may fluctuate due to the exchange rate). The generic drugs produced abroad are basically the same as the original drugs at home and abroad. There may be differences in the prices of different specifications of drugs.